Suggestions
Aliya Omer
Vice President and Head of Global Portfolio and Program Strategy at Kite Pharma
Aliya Z. Omer is a prominent figure in the pharmaceutical industry, currently serving as the Vice President and Head of Global Portfolio and Program Strategy at Kite Pharma, a leading company in CAR T-cell therapy, which is a revolutionary approach to cancer treatment. She has been in this role since January 2021 and is responsible for shaping the long-term portfolio and pipeline strategy of the organization, emphasizing collaboration across various functions from research to marketing.12
Education and Early Career
Omer holds a Bachelor of Science in Materials Science Engineering and Biomedical Engineering from Carnegie Mellon University, where she initially pursued medicine before shifting her focus to engineering. She also earned an MBA from INSEAD.21 Her career began at Johnson & Johnson, followed by significant roles at Novartis, where she advanced through various leadership positions in oncology before joining Kite Pharma.2
Leadership and Advocacy
In addition to her strategic role at Kite Pharma, Omer is actively involved in diversity, equity, and inclusion (DEI) initiatives. She co-chaired DEI efforts at Novartis and currently sits on the People and Culture Advisory Council for Gilead, Kite's parent company. Omer is a strong advocate for creating inclusive environments that empower diverse voices within organizations.12
Personal Insights
Omer emphasizes the importance of psychological safety and belonging within teams to foster innovation. She believes that effective leadership requires curiosity, vulnerability, and humility, qualities she has cultivated throughout her career.1 As a former competitive athlete and the first Indian woman on Carnegie Mellon’s basketball team, she draws on her experiences to inspire others in her leadership journey.1
Her approach combines technical expertise with a commitment to mentorship and advocacy for underrepresented groups in the workplace, making her a notable leader in the pharmaceutical sector.
